Segment Overview and Major Growth Areas in the Nucleic Acid Therapeutics Market

The nucleic acid therapeutics market is on the brink of rapid expansion, fueled by groundbreaking advancements and increasing adoption across several fronts. As gene-editing technologies and delivery systems evolve, this sector is set to redefine treatment approaches for a variety of diseases by 2030. Here's a detailed overview of the market's value, key players, emerging trends, and major segments shaping the future of nucleic acid therapies.

Nucleic Acid Therapeutics Market Size and Growth Projections
The market for nucleic acid therapeutics is anticipated to experience swift growth, reaching a valuation of $14.07 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 15.1%. Driving this surge are innovations such as CRISPR and other gene-editing techniques, the increasing use of lipid nanoparticle (LNP) delivery systems, and the growing preference for personalized nucleic acid treatments. Additionally, collaborations between pharmaceutical and biotech firms, along with rising investments in RNA-based therapies, contribute significantly to the market's upward trajectory. Key trends emerging during this period include the wider adoption of antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) therapies, the development of gene-editing therapeutics based on CRISPR, and progress in targeted treatments for neuromuscular, metabolic, and oncological diseases. Investment is also growing in both viral and non-viral delivery platforms, with new therapeutic classes like long non-coding RNA (lncRNA) and microRNA (miRNA) gaining prominence.

Download a free sample of the nucleic acid therapeutics market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Companies Leading the Nucleic Acid Therapeutics Industry
Several prominent organizations are at the forefront of the nucleic acid therapeutics landscape, including Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, and Copernicus Therapeutics Inc. These companies are actively developing innovative therapies and expanding their pipelines to meet the growing demand for precision medicines.

Strategic Acquisition Strengthening Market Position
In June 2025, Novartis AG, headquartered in Switzerland, completed the acquisition of Regulus Therapeutics Inc., a US-based biotech firm specializing in microRNA therapeutics. Although the financial terms were not disclosed, this move was aimed at boosting Novartis's RNA-targeted drug development capabilities, enhancing its portfolio in rare and chronic diseases, and accelerating the advancement of next-generation treatments leveraging Regulus's microRNA expertise. This strategic acquisition underscores the importance of microRNA-based therapies in the evolving nucleic acid therapeutics market.

View the full nucleic acid therapeutics market report:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Market Trends Highlight Focus on Precision Medicine
Industry leaders are increasingly focused on creating innovative products such as antisense oligonucleotide therapies, which precisely target and silence genes responsible for various diseases. These therapies offer a personalized approach for treating genetic disorders and rare diseases by using short synthetic strands of DNA or RNA to interfere with gene expression. A notable example is Ionis Pharmaceuticals Inc., a US-based biotech company that, in December 2024, received FDA approval for TRYNGOLZ (olezarsen). This drug is designed as an adjunct to diet for adults suffering from familial chylomicronemia syndrome (FCS), a rare condition marked by severe hypertriglyceridemia and heightened risk of acute pancreatitis. TRYNGOLZ is the first FDA-approved treatment to achieve significant and sustained triglyceride reduction in these patients, along with a meaningful decrease in acute pancreatitis incidence, administered conveniently via a once-monthly auto-injector.

Nucleic Acid Therapeutics Market Segmentation Overview
The nucleic acid therapeutics market is categorized across multiple dimensions to better understand its scope:
1) Therapy Type:
- Antisense Oligonucleotides (ASOs)
- Small Interfering RNA (siRNA)
- Gene Therapies
- Aptamers
- Other Therapy Types
2) Therapeutic Area:
- Neuromuscular Disorders
- Metabolic Disorders
- Cardiovascular Disorders
- Ophthalmological Disorders
- Oncological Disorders
- Other Therapeutic Areas
3) Route of Administration:
- Intravenous
- Subcutaneous
- Other Routes
4) Delivery Method:
- Viral Vector-Based Systems
- Non-Viral Delivery Systems
5) End-Use:
- Pharmaceutical Companies
- Government and Academic Research Institutes
- Biotech Companies

More granular classification includes:
- For ASOs: Phosphorothioate ASOs, 2'-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs
- For siRNA: Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA
- For Gene Therapies: Viral and Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs
- For Aptamers: RNA Aptamers, DNA Aptamers, Spiegelmers, Pegylated Aptamers
- For Other Therapies: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, RNA Editing Therapies, Ribozymes

This comprehensive segmentation framework highlights the diversity and specialization within the nucleic acid therapeutics field, reflecting its complexity and rapid innovation.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables


Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at marketing@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.